120 related articles for article (PubMed ID: 38614979)
21. Racial/Ethnic Differences in Pathologic Complete Response to Neoadjuvant Chemotherapy and Survival Among Early-Stage, Erb-B2 Receptor Tyrosine Kinase 2-Low Breast Cancer Patients.
Freeman JQ; Li JL; Omoleye OJ
J Breast Cancer; 2024 Feb; 27(1):54-60. PubMed ID: 38233338
[TBL] [Abstract][Full Text] [Related]
22. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract][Full Text] [Related]
23. Palliative Care Use Trends, Racial/Ethnic Disparities, and Overall Survival Differences Among Patients With Metastatic Breast Cancer.
Freeman JQ; Omoleye OJ; Zhao F; Huo D
J Palliat Med; 2024 Feb; ():. PubMed ID: 38301120
[No Abstract] [Full Text] [Related]
24. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis.
Stabellini N; Cao L; Towe CW; Luo X; Amin AL; Montero AJ
Front Oncol; 2023; 13():1115208. PubMed ID: 37168373
[TBL] [Abstract][Full Text] [Related]
25. Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.
Carbajal-Ochoa WH; Johnson D; Alvarez A; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2023 Sep; 201(2):275-287. PubMed ID: 37442877
[TBL] [Abstract][Full Text] [Related]
26. 21-Gene Recurrence Score Assay Predicts Benefit of Post-Mastectomy Radiotherapy in T1-2 N1 Breast Cancer.
Goodman CR; Seagle BL; Kocherginsky M; Donnelly ED; Shahabi S; Strauss JB
Clin Cancer Res; 2018 Aug; 24(16):3878-3887. PubMed ID: 29685878
[No Abstract] [Full Text] [Related]
27. Role of 21-Gene Recurrence Score in Predicting Prognostic Benefit of Radiation Therapy After Breast-Conserving Surgery for T1N0 Breast Cancer.
Chevli N; Haque W; Tran KT; Farach AM; Schwartz MR; Hatch SS; Butler EB; Teh BS
Pract Radiat Oncol; 2023; 13(3):e230-e238. PubMed ID: 36038115
[TBL] [Abstract][Full Text] [Related]
28. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Kantor O; King TA; Jones A; Glass C; Leonard SJ; Ogayo ER; Mayer EL; Chavez-MacGregor M; Newman LA; Freedman RA; Mittendorf EA
Ann Surg Oncol; 2023 Dec; 30(13):8404-8411. PubMed ID: 37777685
[TBL] [Abstract][Full Text] [Related]
29. Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis.
John EM; McGuire V; Kurian AW; Koo J; Shariff-Marco S; Gomez SL; Cheng I; Keegan THM; Kwan ML; Bernstein L; Vigen C; Wu AH
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):351-363. PubMed ID: 33355191
[TBL] [Abstract][Full Text] [Related]
30. Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer.
Nash AL; Ren Y; Plichta JK; Rosenberger LH; van den Bruele AMB; DiNome ML; Westbrook K; Hwang ES
Ann Surg Oncol; 2023 Apr; 30(4):2130-2139. PubMed ID: 36611067
[TBL] [Abstract][Full Text] [Related]
31. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.
Kim G; Pastoriza JM; Qin J; Lin J; Karagiannis GS; Condeelis JS; Yothers G; Anderson S; Julian T; Entenberg D; Rohan TE; Xue X; Sparano JA; Oktay MH
Cancer; 2022 Jul; 128(14):2728-2735. PubMed ID: 35578919
[TBL] [Abstract][Full Text] [Related]
32. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
33. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Losk K; Freedman RA; Laws A; Kantor O; Mittendorf EA; Tan-Wasielewski Z; Trippa L; Lin NU; Winer EP; King TA
Breast Cancer Res Treat; 2021 Jan; 185(1):215-227. PubMed ID: 32939592
[TBL] [Abstract][Full Text] [Related]
34. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US.
Shubeck S; Zhao F; Howard FM; Olopade OI; Huo D
JAMA Netw Open; 2023 Mar; 6(3):e235834. PubMed ID: 36995711
[TBL] [Abstract][Full Text] [Related]
35. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Lund MJ; Mosunjac M; Davis KM; Gabram-Mendola S; Rizzo M; Bumpers HL; Hearn S; Zelnak A; Styblo T; O'Regan RM
Cancer; 2012 Feb; 118(3):788-96. PubMed ID: 21720988
[TBL] [Abstract][Full Text] [Related]
36. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
[TBL] [Abstract][Full Text] [Related]
37. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer.
Lee J; Lee YJ; Bae SJ; Baek SH; Kook Y; Cha YJ; Lee JW; Son BH; Ahn SH; Lee HJ; Gong G; Jeong J; Lee SB; Ahn SG
JAMA Netw Open; 2023 Aug; 6(8):e2330961. PubMed ID: 37647069
[TBL] [Abstract][Full Text] [Related]
38. Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region.
Davis Lynn BC; Chernyavskiy P; Gierach GL; Rosenberg PS
J Natl Cancer Inst; 2022 Feb; 114(2):263-270. PubMed ID: 34508608
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer.
Kerin EP; Davey MG; McLaughlin RP; Sweeney KJ; Barry MK; Malone CM; Elwahab SA; Lowery AJ; Kerin MJ
Breast; 2022 Dec; 66():227-235. PubMed ID: 36335747
[TBL] [Abstract][Full Text] [Related]
40. Racial and Ethnic Disparities in Breast Cancer Survival: Emergence of a Clinically Distinct Hispanic Black Population.
Goel N; Yadegarynia S; Lubarsky M; Choi S; Kelly K; Balise R; Kesmodel SB; Kobetz E
Ann Surg; 2021 Sep; 274(3):e269-e275. PubMed ID: 34132699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
